Condensed Consolidated Statements of Operations - USD ($) shares in Thousands		3 Months Ended
		Mar. 31, 2020	Mar. 31, 2019
Income Statement [Abstract]
Revenues		$ 441,000,000	$ 416,800,000
Operating expenses:
Salaries and benefits		140,400,000	129,200,000
Supplies		129,300,000	115,000,000
Professional and medical fees		46,800,000	35,100,000
Lease expense		21,300,000	20,600,000
Other operating expenses		28,400,000	26,200,000
Cost of revenues		366,200,000	326,100,000
General and administrative expenses		22,800,000	21,700,000
Depreciation and amortization		21,800,000	18,800,000
Income from equity investments		(2,000,000)	(2,000,000)
Loss on disposals and deconsolidations, net		3,500,000	600,000
Transaction and integration costs		5,500,000	2,000,000
Litigation settlement		1,200,000	0
Other income		(1,500,000)	0
Total operating expenses		417,500,000	367,200,000
Operating income		23,500,000	49,600,000
Tax receivable agreement expense		0	(2,400,000)
Interest expense, net		(47,100,000)	(42,000,000)
(Loss) income before income taxes		(23,600,000)	5,200,000
Income tax (benefit) expense		(15,200,000)	1,700,000
Net (loss) income		(8,400,000)	3,500,000
Less: Net income attributable to non-controlling interests		(19,100,000)	(23,600,000)
Net loss attributable to Surgery Partners, Inc.		(27,500,000)	(20,100,000)
Less: Amounts attributable to participating securities		(9,500,000)	(8,500,000)
Net loss attributable to common stockholders		$ (37,000,000)	$ (28,600,000)
Net loss per share attributable to common stockholders
Basic (in USD per share)		$ (0.76)	$ (0.60)
Diluted (in USD per share)	[1]	$ (0.76)	$ (0.60)
Weighted average common shares outstanding
Basic (shares)		48,472	48,047
Diluted (shares)	[1]	48,472	48,047

[1] The impact of potentially dilutive securities for all periods presented was not considered because the effect would be anti-dilutive in those periods.